A Grim Picture, No Matter How You Look At It
This article was originally published in RPM Report
FDA's official list of New Molecular Enitity approvals is increasingly unsatisfactory as a benchmark for analyzing the health of drug development. To address that problem, The RPM Report creates a tally of Innovative Commercial Therapies. By that analysis, the drug approval trends come into sharper focust. But the picture still isn't pretty.
You may also be interested in...
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.
Latest Oncology Center of Excellence initiative is officially a CME effort designed to encourage practitioners to make full use of the information in the approved drug labeling. It is also a surprisingly effective way to explain drug approvals in a flattering light for regulators and sponsors.